Avid Bioservices Inc (CDMO)

[Protector]

exwannebe, let's just disagree about that. PPHM uses RECIST as do most other pharma/biotechs for tumour response qualification.

See point 4.3 in this RECIST document

4. Tumour response evaluation
...
4.3. Response criteria
This section provides the definitions of the criteria used to
determine objective tumour response for target lesions.

4.3.1. Evaluation of target lesions
Complete Response (CR): Disappearance of all target lesions.
Any pathological lymph nodes (whether target or
non-target) must have reduction in short axis to
<10 mm.

Partial Response (PR): At least a 30% decrease in the sum of
diameters of target lesions, taking as reference the
baseline sum diameters.

Progressive Disease (PD): At least a 20% increase in the sum
of diameters of target lesions, taking as reference
the smallest sum on study (this includes the baseline
sum if that is the smallest on study). In addition to
the relative increase of 20%, the sum must also demonstrate
an absolute increase of at least 5 mm. (Note:
the appearance of one or more new lesions is also
considered progression).

Stable Disease (SD): Neither sufficient shrinkage to qualify for
PR nor sufficient increase to qualify for PD, taking as
reference the smallest sum diameters while on study

Stable Disease (SD) is a RECIST response level and matches what i described, a tumour that does NOT progress any more but also does NOT shrink meaningfully. PPHM uses RECIST for all its tumour progression reporting of its clinical studies.

Based on the above those are clearly in the type of responses to a drug. They had to be because a drug that stops your cancer from progressing, even without the least little bit of shrinking, is a valuable drug. It buys at least time.

PS: Dr. Kaplan (from the Kaplan curve) worked on this document.